



**ESPS PEER-REVIEW REPORT**

**Name of journal:** World Journal of Gastroenterology

**ESPS manuscript NO:** 30721

**Title:** Investigation of mitigating effect of colon-specific prodrugs of boswellic acid on TNBS-induced colitis in Wistar rats: Design, kinetics and biological evaluation

**Reviewer's code:** 00035901

**Reviewer's country:** Japan

**Science editor:** Yuan Qi

**Date sent for review:** 2016-10-14 21:49

**Date reviewed:** 2016-11-15 11:38

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
		BPG Search:	<input checked="" type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

**COMMENTS TO AUTHORS**

The authors demonstrated the efficacy of colon-specific prodrugs of BA on TNBS-induced colitis in mice. The present study was well organized and well investigated, and will give us important information especially in the field of IBD. To improve the quality of the present paper, the authors should revise it according to our suggestions, 1) The introduction is extremely too long, especially for general concept for the treatment of IBD. The authors should shorten the introduction. 2) The authors use the "colon-specific" prodrug. However, the prodrug was changed into BBA by the action of N-acyl amidase of microbiota. The authors should clarify the distribution of N-acyl amidase (+) microbiota in the GI tract. 3) In the patients with IBD, the dysbiosis in intestinal microbiota has been reported recently in animal model as well as human. Does these dysbiosis affect on the activation of pro-drug to BBA?